The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
 
Jin Won Kim
No Relationships to Disclose
 
Koung Jin Suh
No Relationships to Disclose
 
Ji-Won Kim
No Relationships to Disclose
 
Jin Hyun Park
No Relationships to Disclose
 
Ki Hwan Kim
No Relationships to Disclose
 
Yu Jung Kim
No Relationships to Disclose
 
Jin-Soo Kim
Stock and Other Ownership Interests - Chong Kun Dang Pharmaceutical; DAEHWA Pharmaceutical
Honoraria - AstraZeneca; Boehringer Ingelheim; CJ Healthcare; DAEHWA Pharmaceutical; Lilly; Merck
Consulting or Advisory Role - CJ Healthcare; Lilly
Research Funding - Alpha Biopharma; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chong Kun Dang Pharmaceutical; CJ Healthcare; Hanmi; IL-Yang Pharm; Lilly; Merck; MSD; Novotech; Ono Pharmaceutical; Pfizer; Sanofi; Yuhan
Expert Testimony - CJ Healthcare
 
Jee Hyun Kim
No Relationships to Disclose
 
In Sil Choi
No Relationships to Disclose